Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Top Cited Papers
Open Access
- 4 July 2013
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 122 (1), 23-36
- https://doi.org/10.1182/blood-2013-01-306647
Abstract
Gene therapy products for the treatment of genetic diseases are currently in clinical trials, and one of these, an adeno-associated viral (AAV) product, has recently been licensed. AAV vectors have achieved positive results in a number of clinical and preclinical settings, including hematologic disorders such as the hemophilias, Gaucher disease, hemochromatosis, and the porphyrias. Because AAV vectors are administered directly to the patient, the likelihood of a host immune response is high, as shown by human studies. Preexisting and/or recall responses to the wild-type virus from which the vector is engineered, or to the transgene product itself, can interfere with therapeutic efficacy if not identified and managed optimally. Small-scale clinical studies have enabled investigators to dissect the immune responses to the AAV vector capsid and to the transgene product, and to develop strategies to manage these responses to achieve long-term expression of the therapeutic gene. However, a comprehensive understanding of the determinants of immunogenicity of AAV vectors, and of potential associated toxicities, is still lacking. Careful immunosurveillance conducted as part of ongoing clinical studies will provide the basis for understanding the intricacies of the immune response in AAV-mediated gene transfer, facilitating safe and effective therapies for genetic diseases.Keywords
This publication has 126 references indexed in Scilit:
- Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueGene Therapy, 2012
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsJAMA Ophthalmology, 2012
- A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8Molecular Therapy, 2011
- Adeno-associated Virus Vectors Serotype 2 Induce Prolonged Proliferation of Capsid-Specific CD8+ T Cells in MiceMolecular Therapy, 2011
- Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical ApplicationMolecular Therapy, 2010
- Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2DAnnals of Neurology, 2010
- Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B DogsMolecular Therapy, 2010
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationJournal of Medical Virology, 2008
- Enhancing transduction of the liver by adeno-associated viral vectorsGene Therapy, 2008